<DOC>
	<DOCNO>NCT00232635</DOCNO>
	<brief_summary>Objectives Primary Objectives : - Pilot Study : A preliminary assessment exposure safety oral A-60444 post-stem cell transplant patient RSV infection . - Main Study : To determine antiviral effect oral A-60444 versus placebo post-stem cell transplant patient RSV infection ass safety oral A-60444 post-stem cell transplant patient RSV infection . Secondary Objectives : - To study pharmacokinetics A-60444 presence concomitant medication immunosuppressant antifungal , post-stem cell transplant patient RSV infection . Sample Size : Six patient include open , pilot phase study option include 22 patient main , placebo-controlled study , depend pilot study finding . An independent Data Safety Monitoring Board assess finding pilot study .</brief_summary>
	<brief_title>A Study Safety Efficacy A-60444 Adults With Respiratory Syncytial Virus ( RSV ) Infection Following HSCT</brief_title>
	<detailed_description>Clinical record daily . A-60444 PK study pre-dose peak dose last day ( Day 5 ) dosing .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>1 . Patients diagnose RSV infection stem cell transplant . 2 . Female patient must nonchildbearing potential negative pregnancy test prior study start deem risk become pregnant . Females nonchildbearing potential defined woman hysterectomy , bilateral oophorectomy , tubal ligation , postmenopausal least two year ; consider sterile due recent chemotherapy . 3 . Aged 18 65 year . 4 . Patients give write informed consent participate study . 5 . Patients willing able comply protocol study procedure . 1 . Patients receive investigational drug within one month precede start dosing . 2 . Patients document history allergy benzodiazepine . 3 . Patients significant hepatic impairment ( alanine transaminase [ ALT ] 5 x upper level normal [ ULN ] , total bilirubin 3 x ULN ) . Biochemistry data collect four week prior screen acceptable . 4 . Patients , opinion general practitioner Investigator , participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>RSV</keyword>
	<keyword>HSCT</keyword>
	<keyword>HEMATOPOIETIC STEM CELL TRANSPL</keyword>
</DOC>